SK Biopharm Announces Senobamate Launch in Brazil, Partners with Eurofarma on July 29

SK-10.72%
According to Yonhap Infomax, SK Biopharm announced today (July 29) a strategic partnership with Brazilian pharmaceutical company Eurofarma to launch epilepsy treatment Senobamate in Brazil next month. The two companies signed a memorandum of understanding (MOU) in São Paulo. Senobamate will be officially released in August following its prior launches in Peru and Chile, marking SK Biopharm's entry into Latin America's largest pharmaceutical market. The partnership leverages Eurofarma's local regulatory, distribution, and commercialization networks to expand the product's regional reach.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments